Instrument Inactif

Gouvernance NEOPROBE OTC Bulletin Board

NEOP

US6405181065

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

07/11	Retrait d'une requête visant à limiter les pouvoirs du débiteur en possession dans la faillite de Navidea Biopharmaceuticals, Inc.	CI
03/11	Navidea Biopharmaceuticals : une motion demande la limitation des pouvoirs du débiteur en possession ou le rejet de la procédure de faillite	CI

Comité Exécutif: NEOPROBE

Dirigeant

Fonctions occupéesDepuis

Craig Dais

60 ans

Director of Finance/CFO

28/07/2023

Composition du Conseil d'Administration: NEOPROBE

Administrateur

ComitésDepuis

John Scott

71 ans

Compensation Committee	08/07/2021
Governance Committee	08/07/2021
Nominating Committee	08/07/2021

Anciens Dirigeants et Administrateurs: NEOPROBE

Insider

Fonctions occupées

DepuisJusqu'au

Malcolm Witter

Director/Board Member	28/12/2020	03/08/2023
Independent Dir/Board Member	28/12/2020	03/08/2023

Amit Bhalla

Director/Board Member	-	11/07/2023
Chairman	04/05/2021	-
Independent Dir/Board Member	04/05/2021	11/07/2023

Michael Rosol

Chief Tech/Sci/R&D Officer

17/12/2018

30/03/2023

Jed Latkin

Comptroller/Controller/Auditor	09/05/2017	24/10/2021
Director/Board Member	01/10/2018	24/10/2021
Chief Executive Officer	14/08/2018	24/10/2021
Chief Operating Officer	01/04/2016	24/10/2021
Director of Finance/CFO	09/05/2017	24/10/2021
Investor Relations Contact	-	-
Public Communications Contact	-	24/10/2021
Corporate Secretary	09/05/2017	-
Treasurer	09/05/2017	-

S. Rouan

Chairman	01/12/2018	14/09/2021
Independent Dir/Board Member	01/12/2018	14/09/2021

Claudine Bruck

Director/Board Member	05/03/2018	14/09/2021
Independent Dir/Board Member	05/03/2018	14/09/2021

Joel Harrison Kaufman

Investor Relations Contact	-	07/05/2021
Corporate Officer/Principal	-	07/05/2021

Michael Rice

Director/Board Member	04/05/2016	-
Chairman	-	04/05/2021
Independent Dir/Board Member	04/05/2016	04/05/2021

Adam Cutler

Director/Board Member	01/12/2018	04/05/2021
Independent Dir/Board Member	01/12/2018	04/05/2021

Frederick Cope

Chief Tech/Sci/R&D Officer

15/02/2009

30/10/2018

Mike M. Goldberg

Director/Board Member	16/11/2013	14/08/2018
Chief Executive Officer	30/05/2014	14/08/2018
Chairman	31/03/2016	22/09/2016
Independent Dir/Board Member	-	22/09/2016
President	22/09/2016	14/08/2018

Mark Greene

Director/Board Member	23/03/2016	14/08/2018
Independent Dir/Board Member	23/03/2016	14/08/2018

Eric Rowinsky

Director/Board Member	26/05/2010	22/09/2016
Chairman	22/09/2016	31/03/2018
Independent Dir/Board Member	08/12/2011	31/03/2018

Tony Fiorino

Director/Board Member	23/03/2016	09/10/2017
Independent Dir/Board Member	23/03/2016	09/10/2017

Thomas Klima

Corporate Officer/Principal

05/01/2015

08/03/2017

Brent Larson

Director of Finance/CFO	01/07/1996	09/05/2016
Corporate Secretary	01/07/1996	06/10/2016
Treasurer	01/07/1996	06/10/2016

Ricardo Gonzalez

Director/Board Member	05/02/2015	13/05/2016
Chief Executive Officer	13/10/2014	13/05/2016
President	13/10/2014	13/05/2016

Gordon A. Troup

Director/Board Member	11/01/2016	28/04/2016
Chairman	17/08/2011	11/01/2016
Independent Dir/Board Member	24/07/2008	11/01/2016

Anton G. Gueth

Director/Board Member	04/06/2015	11/01/2016
Chairman	11/01/2016	31/03/2016
Independent Dir/Board Member	04/06/2015	11/01/2016

Brendan A. Ford

Director/Board Member	01/07/2010	23/03/2016
Independent Dir/Board Member	01/07/2010	23/03/2016

Perry Karsen

Director/Board Member

17/02/2014

16/07/2015

Peter Drake

Director/Board Member	19/04/2011	16/07/2015
Independent Dir/Board Member	08/12/2011	16/07/2015

Thomas Tulip

Corporate Officer/Principal	02/06/2011	31/05/2015
President	01/05/2013	23/01/2015

Cornelia B. Reininger

Chief Tech/Sci/R&D Officer

01/11/2012

31/05/2015

Michael Tomblyn

Chief Tech/Sci/R&D Officer

05/01/2015

Mark Pykett

Director/Board Member	01/11/2010	30/05/2014
Chief Executive Officer	19/04/2011	30/05/2014
Corporate Officer/Principal	17/11/2010	19/04/2011

Jess Emery Jones

Director/Board Member	19/04/2011	09/07/2013
Independent Dir/Board Member	18/04/2011	09/07/2013

David Colborn

Chief Tech/Sci/R&D Officer

01/05/2012

David C. Bupp

Director/Board Member	01/04/2011	04/01/2012
President	01/12/1989	19/04/2011

Carl J. Aschinger

Director/Board Member	01/06/2004	23/07/2009
Chairman	23/07/2009	16/08/2011

Fred B. Miller

Director/Board Member

01/01/2002

15/08/2011

Owen E. Johnson

Director/Board Member

01/07/2007

15/08/2011

Kirby I. Bland

Director/Board Member

01/05/2004

01/12/2010

J. Frank Whitley

Director/Board Member

01/05/1994

16/07/2010

Reuven Avital

Director/Board Member

01/01/2002

16/07/2010

Julius R. Krevans

Chairman

01/07/2007

Carl M. Bosch

Chief Tech/Sci/R&D Officer

25/04/2007

Rodger A. Brown

General Counsel

01/07/1998

John L. Ridihalgh

Chief Executive Officer	01/01/1984	01/11/1991
Chief Executive Officer	01/06/1992	01/02/1998

David B. Pendleton

Sales & Marketing

Stephen B. Haber

Corporate Officer/Principal

Tom Baker

Investor Relations Contact

David S. Casebier

Corporate Officer/Principal

Richard N. Linder

Corporate Officer/Principal

Mike Russell

Corporate Officer/Principal

Peter Geffen

Corporate Officer/Principal

13/07/2009

Kathleen Squillace

Corporate Officer/Principal

Matthew F. Bowman

Chief Operating Officer	-	-
Sales & Marketing	-	-

Marlin O. Thurston

Corporate Officer/Principal

Nancy Katz

Director/Board Member

Susan M. Flint

Chief Tech/Sci/R&D Officer

Jeffrey Jay

Corporate Officer/Principal

John S. Christie

Director/Board Member

William J. Regan

Compliance Officer	-	-
General Counsel	30/10/2013	-
Corporate Officer/Principal	-	30/10/2013

Sharon Correia

Public Communications Contact	-	-
Corporate Officer/Principal	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	2
Femme	0

Dont comité exécutif

Homme	1
Femme	0

Dont Administrateurs

Homme	1
Femme	0

Navidea Biopharmaceuticals, Inc. est une société biopharmaceutique. La société se concentre sur le développement et la commercialisation d'agents d'immunodiagnostic de précision et d'immunothérapies. Elle développe de multiples produits de précision basés sur sa plateforme Manocept afin d'améliorer les soins aux patients en identifiant les sites et les voies de la maladie non détectée. L'activité de la société se concentre sur deux types principaux de produits pharmaceutiques, tels que les substances diagnostiques, y compris le Tc99m tilmanocept et d'autres applications diagnostiques de sa plateforme Manocept, et les programmes de développement thérapeutique, y compris les applications thérapeutiques de sa plateforme Manocept. Elle a développé des procédés pour produire les quatre premières séries d'immunoconstructions thérapeutiques Manocept, la série Manocept doxorubicine (MAN-DOX), qui est conçue pour cibler spécifiquement et tuer ou modifier les macrophages CD206+ activés en délivrant de la doxorubicine, une série Manocept paclitaxel (MAN-PAC), et une série Manocept Bisphosphonate (MAN-BIS).

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société